Ozempic, also known as semaglutide, is among a host of GLP-1 agonists that researchers are exploring and the FDA is approving for the treatment of diabetes, obesity, cardiovascular risk reduction, weight management, and perhaps chronic kidney disease
Demonstrated benefits on intestinal health New research from the University of Tartu, Estonia, and the National Research Council, Italy, have shown beneficial effects of ME-3 on gut microbiota composition and reduction of intestinal permeability
GLP-1 prescriptions may vary based on your insurance coverage
With advances in proteincofactor interaction kinetics and structural prediction algorithms, gene therapies targeting riboflavin pathways are poised to move from proof-of-concept toward precision clinical practice, offering hope for patients with refractory neurometabolic diseases